Thursday, 18 July 2019

AMRI acquires Oso Biopharmaceuticals at $110 mn

02 July 2014 | News | By BioSpectrum Bureau

AMRI has said that it financed the transaction with cash on hand

AMRI has said that it financed the transaction with cash on hand

Singapore: US based contract research firm, AMRI, with operations in Asia, has acquired Oso Biopharmaceuticals Manufacturing, a former portfolio company of Altaris Capital Partners and a contract manufacturer of highly complex injectable drug products, in $110 million deal.

Altaris Capital Partners is a US based investment firm focused exclusively on healthcare industry.

The transaction is consistent with AMRI's strategy to be the preeminent supplier of custom and complex drug product development and manufacturing services to the pharmaceutical industry.

OsoBio has its strength in large-scale commercial production and is expected to complement AMRI's early stage drug product manufacturing capabilities.

AMRI informed that the company financed the transaction with cash on hand and anticipates full year run-rate synergies of approximately $3.0 million of EBITDA within 12 months of closing.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is Blockchain offering a solution to the healthcare industry?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls